Japan Long-term Safety for Tiotropium Plus Olodaterol
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety of 52 weeks once daily treatment
with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT
Inhaler) in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD).